Anzeige
Meldung des Tages: Goldchance mit Substanz: Warum dieses Projekt Investoren aufhorchen lässt

Icecure Medical Aktie News

Aktie
WKN:  A1W1LG ISIN:  IL0011224156 US-Symbol:  ICCM Branche:  Gesundheitswesen: Ausstattung u. Produkte Land:  Israel
0,552 $
-0,048 $
-8,00%
0,46833 € 05.02.26
Depot/Watchlist
Marktkapitalisierung *
34,19 Mio. €
Streubesitz
52,20%
KGV
-
Index-Zuordnung
-

Icecure Medical News

28.01.26 - PR Newswire
IceCure Celebrates American Society of Breast Surgeons' (ASBrS) Proposed Breast Cancer Treatment Guidelines Which Include Cryoablation for Low-Risk Breast Cancer
IceCure Celebrates American Society of Breast Surgeons' (ASBrS) Proposed Breast Cancer Treatment Guidelines Which Include Cryoablation for Low-Risk Breast Cancer PR ...
12.01.26 - PR Newswire
IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense® Sales
IceCure CEO Issues Letter to Shareholders: Reports Record Fourth Quarter and Full Year 2025 ProSense® Sales PR Newswire
17.12.25 - PR Newswire
IceCure Expected to Report Record Fourth Quarter Sales in North America Driven by Recent FDA Clearance of ProSense® Cryoablation for Low-Risk Breast Cancer
IceCure Expected to Report Record Fourth Quarter Sales in North America Driven by Recent FDA Clearance of ProSense® Cryoablation for Low-Risk Breast Cancer PR Newswire
10.12.25 - PR Newswire
IceCure's ProSense® Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting
IceCure's ProSense® Cryoablation Featured in 4 Independent Breast Cancer Studies Presented at Radiological Society of America 2025 Annual Meeting PR Newswire
05.12.25 - PR Newswire
IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes
IceCure Receives Notice of Patent Allowance in China for a Novel Cryogen Flow Control to Optimize Patient Cryoablation Outcomes PR Newswire
19.11.25 - PR Newswire
IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025
IceCure Reports Financial & Operational Results for the Nine Months Ended September 30, 2025 PR Newswire
18.11.25 - PR Newswire
IceCure's ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer
IceCure's ProSense® Cryoablation System Receives Regulatory Approval in Switzerland for Indications Including Breast, Lung, Liver, and Kidney Cancer PR Newswire
14.11.25 - PR Newswire
IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification
IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification PR Newswire
12.11.25 - PR Newswire
IceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025
IceCure Medical to Report Third Quarter 2025 Financial and Operating Results on November 19, 2025 PR Newswire
10.11.25 - PR Newswire
IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction
IceCure Promotes Shay Levav to Chief Operating Officer as Company Ramps up for Increased Commercial Traction PR Newswire
03.11.25 - PR Newswire
IceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-Specific 5-year Survival
IceCure's Cryoablation System Combined with Radiation Therapy Successfully Treats Non-Small Cell Lung Cancer (NSCLC) with 92% Disease-​Specific 5-year Survival PR Newswire
13.10.25 - PR Newswire
IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances
IceCure's ProSense® Showcased at TME Fall Summit: "Take the Lead in Breast Cancer Care" Roundtable Highlighting Cryoablation Advances PR Newswire
09.10.25 - PR Newswire
IceCure Medical to Attend the 2025 Maxim Growth Summit
IceCure Medical to Attend the 2025 Maxim Growth Summit PR Newswire
03.10.25 - PR Newswire
IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in Giving Women with Breast Cancer Minimally Invasive Care
IceCure Medical's ProSense® Cryoablation Granted FDA Marketing Authorization for Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above: Significant Development in ...
03.10.25 - PR Newswire
IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above
IceCure Receives FDA Marketing Authorization for ProSense® Cryoablation for the Treatment of Low-Risk Breast Cancer in Women Aged 70 and Above PR Newswire
30.09.25 - PR Newswire
IceCure's ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies Presented
IceCure's ProSense® at the European Society of Breast Imaging Congress 2025: Unlocking De-​Escalation of Care in Breast Cancer, Positive Results from 5 Independent Studies ...
22.09.25 - PR Newswire
IceCure's ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented
IceCure's ProSense® Featured at CIRSE 2025 Annual Meeting: Positive Clinical Results with Cryoablation from 4 Independent Studies Presented PR Newswire
18.09.25 - PR Newswire
IceCure Granted Notice of Allowance for U.S. Patent for its Next-Generation XSense™ Cryoprobes
IceCure Granted Notice of Allowance for U.S. Patent for its Next-​Generation XSense™ Cryoprobes PR Newswire
16.09.25 - PR Newswire
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals PR Newswire
16.09.25 - PR Newswire
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals
Cancer Immunotherapy Surge Drives $258B Market as FDA Accelerates Approvals PR Newswire

Newssuche

Videos

newspaper
05.02.26 +8,47%
Technical Trading: Pfund Short im Februar
GBP/USD Short Typ: Turbo Open End WKN: VH3A2E Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »